ACG has issued a statement urging clinicians to interpret American Cancer Society’s revised colorectal cancer screening ...
ACG posed several key questions and developed practical recommendations for practice providers. The recommendations were crafted through a focused literature search and supplemented by existing ...
New blood-based screening tests for colorectal cancer (CRC) offered fewer benefits at higher cost versus other screening options, a cost-effectiveness modeling study suggested. In a comparison against ...
Geneoscopy, Inc., a life sciences company focused on developing diagnostic tests for the advancement of gastrointestinal ...
Cologuard® CRC Screening Test Most Cost-Effective Test in Medically Underserved Alaska Native People
MADISON, Wis., April 28, 2021 /PRNewswire/ -- Exact Sciences (NASDAQ: EXAS) today announces study results published in Mayo Clinic Proceedings showing that Cologuard (mt-sDNA) is the most ...
Please provide your email address to receive an email when new articles are posted on . LAS VEGAS — Multimodal circulating tumor DNA blood-based colorectal cancer screening tests may have clinically ...
The FDA has approved the Cologuard Plus test, a next-generation, multitarget stool DNA test approved for patients at an average risk for colorectal cancer. The FDA’s approval was based on findings ...
Although considered a single class, fecal immunochemical tests (FITs) vary in their ability to detect advanced colorectal neoplasia (ACN) and should not be considered interchangeable, new research ...
Novel first-generation cell-free DNA blood (cf-bDNA) tests for colorectal cancer (CRC) cost more and are less effective than colonoscopy or stool tests, a new analysis suggests. Researchers estimated ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Freenome, a privately held biotechnology company that has pioneered a comprehensive multiomics platform for early cancer detection with a routine blood ...
WASHINGTON -- A blood-based test for the early detection of colorectal cancer (CRC) met its prespecified sensitivity and specificity endpoints, according to results from the PREEMPT CRC study. Using ...
– As presented later this week at the ASCO GI conference, the large case-control validation study of nearly 1,000 samples highlights a head-to-head comparison with the test's first version, which is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results